{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:35:52Z","timestamp":1791916552761,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,10,4]],"date-time":"2012-10-04T00:00:00Z","timestamp":1349308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00277-012-1575-2","type":"journal-article","created":{"date-parts":[[2012,10,3]],"date-time":"2012-10-03T07:41:30Z","timestamp":1349250090000},"page":"151-162","source":"Crossref","is-referenced-by-count":17,"title":["Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K\u2013562 with unmodified or chemically modified siRNAs and induction of apoptosis"],"prefix":"10.1007","volume":"92","author":[{"given":"Bur\u00e7in Tezcanl\u0131","family":"Kaymaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Selvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cumhur","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011fda\u015f","family":"Aktan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015feg\u00fcl","family":"Dalm\u0131zrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buket","family":"Kosova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,4]]},"reference":[{"key":"1575_CR1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/asheducation-2003.1.132","volume":"1","author":"JV Melo","year":"2003","unstructured":"Melo JV, Hughes TP, Apperley JF (2003) Chronic myeloid leukemia. Hematol Am Soc Hematol Educ Program 1:132\u2013152","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1575_CR2","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Melo JV, Tura S, Giralt S, Talpaz M (2000) Chronic myelogenous leukemia: disease biology and current and future therapeutic strategies. Hematol Am Soc Hematol Educ Program 1:90\u2013109","DOI":"10.1182\/asheducation-2000.1.90"},{"issue":"12","key":"1575_CR3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","volume":"145","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Talpaz M, Giles F, O'Brien S, Cortes J (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145(12):913\u2013923","journal-title":"Ann Intern Med"},{"issue":"5","key":"1575_CR4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2011.01689.x","volume":"87","author":"S Vaidya","year":"2011","unstructured":"Vaidya S, Ghosh K, Vundinti BR (2011) Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol 87(5):381\u2013393","journal-title":"Eur J Haematol"},{"issue":"6","key":"1575_CR5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bcp.2005.12.017","volume":"71","author":"L Valentino","year":"2006","unstructured":"Valentino L, Pierre J (2006) JAK\/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71(6):713\u2013721","journal-title":"Biochem Pharmacol"},{"issue":"Pt 8","key":"1575_CR6","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","volume":"117","author":"JS Rawlings","year":"2004","unstructured":"Rawlings JS, Rosler KM, Harrison DA (2004) The JAK\/STAT signaling pathway. J Cell Sci 117(Pt 8):1281\u20131283","journal-title":"J Cell Sci"},{"issue":"21","key":"1575_CR7","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.onc.1203480","volume":"19","author":"DE Levy","year":"2000","unstructured":"Levy DE, Gilliland DG (2000) Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 19(21):2505\u20132510","journal-title":"Oncogene"},{"issue":"15","key":"1575_CR8","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.1073\/pnas.93.15.7673","volume":"93","author":"JF Bromberg","year":"1996","unstructured":"Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr (1996) Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci U S A 93(15):7673\u20137678","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1575_CR9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","volume":"4","author":"H Yu","year":"2004","unstructured":"Yu H, Jove R (2004) The STATs of cancer\u2014new molecular targets come of age. Nat Rev Cancer 4(2):97\u2013105","journal-title":"Nat Rev Cancer"},{"issue":"49","key":"1575_CR10","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"RL Ilaria Jr","year":"1996","unstructured":"Ilaria RL Jr, Van Etten RA (1996) P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271(49):31704\u201331710","journal-title":"J Biol Chem"},{"issue":"9","key":"1575_CR11","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood.V97.9.2846","volume":"97","author":"NJ Donato","year":"2001","unstructured":"Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M (2001) Down-regulation of interleukin-3\/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood 97(9):2846\u20132853","journal-title":"Blood"},{"issue":"8","key":"1575_CR12","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","volume":"189","author":"M Nieborowska-Skorska","year":"1999","unstructured":"Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B, Skorski T (1999) Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis. J Exp Med 189(8):1229\u20131242","journal-title":"J Exp Med"},{"issue":"1","key":"1575_CR13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","volume":"10","author":"R Catlett-Falcone","year":"1999","unstructured":"Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fern\u00e1ndez-Luna JL, Nu\u00f1ez G, Dalton WS, Jove R (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10(1):105\u2013115","journal-title":"Immunity"},{"issue":"6","key":"1575_CR14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/00001813-200507000-00002","volume":"16","author":"N Jing","year":"2005","unstructured":"Jing N, Tweardy DJ (2005) Targeting Stat3 in cancer therapy. Anticancer Drugs 16(6):601\u2013607","journal-title":"Anticancer Drugs"},{"issue":"26","key":"1575_CR15","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1200\/JCO.2008.21.3264","volume":"27","author":"M Benekli","year":"2009","unstructured":"Benekli M, Baumann H, Wetzler M (2009) Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 27(26):4422\u20134432","journal-title":"J Clin Oncol"},{"issue":"2","key":"1575_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","volume":"8","author":"KA Whitehead","year":"2009","unstructured":"Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8(2):129\u2013138","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1575_CR17","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","volume":"9","author":"YL Chiu","year":"2003","unstructured":"Chiu YL, Rana TM (2003) siRNA function in RNAi: a chemical modification analysis. RNA 9(9):1034\u20131048","journal-title":"RNA"},{"issue":"21","key":"1575_CR18","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","volume":"19","author":"T Bowman","year":"2000","unstructured":"Bowman T, Garcia R, Turkson J, Jove R (2000) STATs in oncogenesis. Oncogene 19(21):2474\u20132488","journal-title":"Oncogene"},{"issue":"5486","key":"1575_CR19","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289(5486):1938\u20131942","journal-title":"Science"},{"issue":"1","key":"1575_CR20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/mt.2008.215","volume":"17","author":"L Crombez","year":"2009","unstructured":"Crombez L, Aldrian-Herrada G, Konate K, Nguyen QN, McMaster GK, Brasseur R, Heitz F, Divita G (2009) A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 17(1):95\u2013103","journal-title":"Mol Ther"},{"issue":"4","key":"1575_CR21","first-page":"945","volume":"8","author":"R Buettner","year":"2002","unstructured":"Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8(4):945\u2013954","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1575_CR22","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.4049\/jimmunol.159.10.4720","volume":"159","author":"SK Chai","year":"1997","unstructured":"Chai SK, Nichols GL, Rothman P (1997) Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159(10):4720\u20134728","journal-title":"J Immunol"},{"issue":"10","key":"1575_CR23","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3109\/10428194.2010.507830","volume":"51","author":"B Kosova","year":"2010","unstructured":"Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N, Dalmizrak A, Kartal M, Gunduz U, Baran Y (2010) Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leuk Lymphoma 51(10):1895\u20131901","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"1575_CR24","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1038\/sj.onc.1206620","volume":"22","author":"MO Nowicki","year":"2003","unstructured":"Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T (2003) Chronic myelogenous leukemia molecular signature. Oncogene 22(25):3952\u20133963","journal-title":"Oncogene"},{"issue":"12","key":"1575_CR25","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1172\/JCI29401","volume":"116","author":"R Piva","year":"2006","unstructured":"Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, Costa G, Ruggeri BA, Cheng M, Chiarle R, Palestro G, Neri A, Inghirami G (2006) Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 116(12):3171\u20133182","journal-title":"J Clin Invest"},{"issue":"12","key":"1575_CR26","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/leu.2008.226","volume":"22","author":"H Quentmeier","year":"2008","unstructured":"Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, R\u00f6hrs S, Romani J, Scherr M, Zaborski M, Drexler HG (2008) SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 22(12):2169\u20132175","journal-title":"Leukemia"},{"issue":"10","key":"1575_CR27","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1182\/blood-2005-08-3181","volume":"107","author":"C Guerzoni","year":"2006","unstructured":"Guerzoni C, Bardini M, Mariani SA, Ferrari-Amorotti G, Neviani P, Panno ML, Zhang Y, Martinez R, Perrotti D, Calabretta B (2006) Inducible activation of CEBPB, a gene negatively regulated by BCR\/ABL, inhibits proliferation and promotes differentiation of BCR\/ABL-expressing cells. Blood 107(10):4080\u20134089","journal-title":"Blood"},{"issue":"1","key":"1575_CR28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0165-4608(03)00155-9","volume":"147","author":"C Ulger","year":"2003","unstructured":"Ulger C, Toruner GA, Alkan M, Mohammed M, Damani S, Kang J, Galante A, Aviv H, Soteropoulos P, Tolias PP, Schwalb MN, Dermody JJ (2003) Comprehensive genome-wide comparison of DNA and RNA level scan using microarray technology for identification of candidate cancer-related genes in the HL-60 cell line. Cancer Genet Cytogenet 147(1):28\u201335","journal-title":"Cancer Genet Cytogenet"},{"key":"1575_CR29","doi-asserted-by":"crossref","unstructured":"Segatto O, Anastasi S, Alem\u00e0 S (2011) Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. J Cell Sci 124(11):1785\u20131793","DOI":"10.1242\/jcs.083303"},{"issue":"23","key":"1575_CR30","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1111\/j.1742-4658.2010.07904.x","volume":"277","author":"MS Shim","year":"2010","unstructured":"Shim MS, Kwon YJ (2010) Efficient and targeted delivery of siRNA in vivo. FEBS J 277(23):4814\u20134827","journal-title":"FEBS J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1575-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-012-1575-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-012-1575-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T23:56:12Z","timestamp":1714434972000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-012-1575-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["1575"],"URL":"https:\/\/doi.org\/10.1007\/s00277-012-1575-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,4]]}}}